Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care System.
Guideline-concordant treatment
Multidisciplinary Thoracic Oncology Conference
Multidisciplinary care
Outcomes
Quality of care
Survival
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
21
12
2020
revised:
14
06
2021
accepted:
24
06
2021
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
1
10
2021
Statut:
epublish
Résumé
We compared NSCLC treatment and survival within and outside a multidisciplinary model of care from a large community health care system. We implemented a rigorously benchmarked "enhanced" Multidisciplinary Thoracic Oncology Conference (eMTOC) and used Tumor Registry data (2011-2017) to evaluate guideline-concordant care. Because eMTOC was located in metropolitan Memphis, we separated non-MTOC patient by metropolitan and regional location. We categorized National Comprehensive Cancer Network guideline-concordant treatment as "preferred," or "appropriate" (allowable under certain circumstances). We compared demographic and clinical characteristics across cohorts using chi-square tests and survival using Cox regression, adjusted for multiple testing. We also performed propensity-matched and adjusted survival analyses. Of 6259 patients, 14% were in eMTOC, 55% metropolitan non-MTOC, and 31% regional non-MTOC cohorts. eMTOC had the highest rates of African Americans (34% versus 28% versus 22%), stages I to IIIB (63 versus 40 versus 50), urban residents (81 versus 78 versus 20), stage-preferred treatment (66 versus 57 versus 48), guideline-concordant treatment (78 versus 70 versus 63), and lowest percentage of nontreatment (6 versus 21 versus 28); all Multidisciplinary NSCLC care planning was associated with significantly higher rates of guideline-concordant care and survival, providing evidence for rigorous implementation of this model of care.
Identifiants
pubmed: 34590046
doi: 10.1016/j.jtocrr.2021.100203
pii: S2666-3643(21)00062-X
pmc: PMC8474211
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100203Informations de copyright
© 2021 The Authors.
Références
J Natl Cancer Inst. 2013 Jan 16;105(2):113-21
pubmed: 23274388
Chest. 2020 Aug;158(2):787-796
pubmed: 32387525
Clin Oncol (R Coll Radiol). 2019 Oct;31(10):688-696
pubmed: 31514942
Lung Cancer. 2014 Mar;83(3):401-7
pubmed: 24491311
Br J Cancer. 2005 Oct 31;93(9):977-8
pubmed: 16234818
Ann Am Thorac Soc. 2017 Mar;14(3):403-411
pubmed: 28118039
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
PLoS One. 2015 May 12;10(5):e0126547
pubmed: 25966317
JAMA. 1988 Sep 23-30;260(12):1743-8
pubmed: 3045356
Thorax. 1998 Jun;53 Suppl 1:S1-8
pubmed: 9713437
Transl Lung Cancer Res. 2018 Feb;7(1):88-102
pubmed: 29535915
JAMA. 2017 Jan 24;317(4):388-406
pubmed: 28118455
J Clin Oncol. 2006 Jul 20;24(21):3498-9
pubmed: 16751437
J Thorac Oncol. 2006 Sep;1(7):692-6
pubmed: 17409938
J Thorac Oncol. 2007 Jan;2(1):69-72
pubmed: 17410013
Clin Lung Cancer. 2018 Jul;19(4):323-330.e3
pubmed: 29544716
J Oncol Pract. 2016 Oct;12(10):888-891
pubmed: 27531378
Clin Lung Cancer. 2018 Jul;19(4):294-300
pubmed: 29934139
Clin Med (Lond). 2012 Feb;12(1):14-8
pubmed: 22372213
J Oncol Pract. 2010 Mar;6(2):61-8
pubmed: 20592777
Cancer. 2018 Sep 15;124(18):3634-3637
pubmed: 30216415
PLoS One. 2020 Oct 8;15(10):e0236503
pubmed: 33031375
Lancet Oncol. 2006 Nov;7(11):886-8
pubmed: 17081913
Cancer. 2018 Sep 15;124(18):3656-3667
pubmed: 30216477
Eur Respir J. 1996 Jan;9(1):5-6
pubmed: 8834325
J Thorac Oncol. 2013 Jan;8(1):68-72
pubmed: 23242439
Thorax. 2015 Feb;70(2):146-51
pubmed: 25182047
Thorax. 2019 Jun;74(6):546-550
pubmed: 30661021
Clin Lung Cancer. 2018 Jul;19(4):346-351
pubmed: 29506890
J Oncol Pract. 2016 Nov;12(11):983-991
pubmed: 27650844